Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease

Valerio Leoni, Caterina Mariotti, Sarah J. Tabrizi, Marta Valenza, Edward J. Wild, Susie M D Henley, Nicola Z. Hobbs, Maria Luisa Mandelli, Marina Grisoli, Ingemar Björkhem, Elena Cattaneo, Stefano Di Donato

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P <0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P <0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.

Original languageEnglish
Pages (from-to)2851-2859
Number of pages9
JournalBrain
Volume131
Issue number11
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Huntington Disease
Cholesterol
24-hydroxycholesterol
Disease Progression
Brain
Neurodegenerative Diseases
Genes
Meals
Fasting

Keywords

  • 24S-hydroxycholesterol
  • Biomarker
  • Caudate volume
  • Gas chromatography-mass spectrometry
  • MRI
  • Oxysterol

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M. D., ... Di Donato, S. (2008). Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain, 131(11), 2851-2859. https://doi.org/10.1093/brain/awn212

Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. / Leoni, Valerio; Mariotti, Caterina; Tabrizi, Sarah J.; Valenza, Marta; Wild, Edward J.; Henley, Susie M D; Hobbs, Nicola Z.; Mandelli, Maria Luisa; Grisoli, Marina; Björkhem, Ingemar; Cattaneo, Elena; Di Donato, Stefano.

In: Brain, Vol. 131, No. 11, 11.2008, p. 2851-2859.

Research output: Contribution to journalArticle

Leoni, V, Mariotti, C, Tabrizi, SJ, Valenza, M, Wild, EJ, Henley, SMD, Hobbs, NZ, Mandelli, ML, Grisoli, M, Björkhem, I, Cattaneo, E & Di Donato, S 2008, 'Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease', Brain, vol. 131, no. 11, pp. 2851-2859. https://doi.org/10.1093/brain/awn212
Leoni, Valerio ; Mariotti, Caterina ; Tabrizi, Sarah J. ; Valenza, Marta ; Wild, Edward J. ; Henley, Susie M D ; Hobbs, Nicola Z. ; Mandelli, Maria Luisa ; Grisoli, Marina ; Björkhem, Ingemar ; Cattaneo, Elena ; Di Donato, Stefano. / Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. In: Brain. 2008 ; Vol. 131, No. 11. pp. 2851-2859.
@article{21b1a475c25e46a8b01aa2c48c20bba2,
title = "Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease",
abstract = "Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P <0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P <0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.",
keywords = "24S-hydroxycholesterol, Biomarker, Caudate volume, Gas chromatography-mass spectrometry, MRI, Oxysterol",
author = "Valerio Leoni and Caterina Mariotti and Tabrizi, {Sarah J.} and Marta Valenza and Wild, {Edward J.} and Henley, {Susie M D} and Hobbs, {Nicola Z.} and Mandelli, {Maria Luisa} and Marina Grisoli and Ingemar Bj{\"o}rkhem and Elena Cattaneo and {Di Donato}, Stefano",
year = "2008",
month = "11",
doi = "10.1093/brain/awn212",
language = "English",
volume = "131",
pages = "2851--2859",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease

AU - Leoni, Valerio

AU - Mariotti, Caterina

AU - Tabrizi, Sarah J.

AU - Valenza, Marta

AU - Wild, Edward J.

AU - Henley, Susie M D

AU - Hobbs, Nicola Z.

AU - Mandelli, Maria Luisa

AU - Grisoli, Marina

AU - Björkhem, Ingemar

AU - Cattaneo, Elena

AU - Di Donato, Stefano

PY - 2008/11

Y1 - 2008/11

N2 - Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P <0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P <0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.

AB - Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P <0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P <0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.

KW - 24S-hydroxycholesterol

KW - Biomarker

KW - Caudate volume

KW - Gas chromatography-mass spectrometry

KW - MRI

KW - Oxysterol

UR - http://www.scopus.com/inward/record.url?scp=55749085638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749085638&partnerID=8YFLogxK

U2 - 10.1093/brain/awn212

DO - 10.1093/brain/awn212

M3 - Article

VL - 131

SP - 2851

EP - 2859

JO - Brain

JF - Brain

SN - 0006-8950

IS - 11

ER -